Novo Nordisk is launching a cheaper authorised version of its blockbuster diabetes drug Ozempic in South Africa, intensifying ...

NFL legend Tom Brady is partnering with eMed to tackle the obesity epidemic by making GLP-1 weight loss medications ...

South African pharmacy group iDexis said on Tuesday it had applied to appeal a court judgment that curbed its production ‌of compounded weight-loss medicines, disputing allegations about product ...

('Cosmos Health' or the 'Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into an agreement for the commercialization of its ...

GLP-1 drugs did not appear to improve diabetes patients' job or marriage prospects, according to a working paper from the ...

The arrival of the monsoon season provides a much needed relief from scorching summer heatwaves, but it simultaneously ...

A network meta-analysis of 19 weight-loss drugs concludes that most obesity drugs don’t improve quality of life or cardiovascular health.

Diabetes remains a global health concern. In 2024, the World Health Organization (WHO) reported that the number of people ...

Australia’s growing appetite for GLP-1 injectable weight-loss drugs has turned the country into a billion-dollar market for US pharmaceutical giant Eli Lilly and its blockbuster treatment, Mounjaro.

The federal government has launched a new program to make GLP-1 weight loss drugs more affordable for older Americans.

Objectives This study aims to investigate the knowledge, attitudes and practices (KAP) regarding diabetic nephropathy among patients with diabetes. Design A cross-sectional survey was conducted.

Introduction Tribal people in India face a growing risk of multimorbidity, primarily from cardiovascular diseases (CVD) due to changing lifestyles and unique socio-cultural and political factors. We ...